Retatrutide Dose

Calculator · Trial data

Retatrutide Calculator

Pick the vial and the water to get mg/mL, mL and U-100 units.

6 min read3 sources
Retatrutide reconstitution calculator
1. Peptide in the vial
2. Bacteriostatic water added

Strength

5 mg/mL

Volume

0.2 mL

U-100

20 units

020406080100
1 mL U-100 syringe, 0 to 100 units, filled to the reading above.
Working from a 10 mg vial? Retatrutide 10 mg at OXpeptides, with its Janoshik report, and bacteriostatic water.

Laboratory arithmetic for a research sample, not a dosing tool.

Three sealed OXpeptides Retatrutide research vials with crimp caps and white lyophilised cakes, on a white background

Our pick

OXpeptides Retatrutide 20 mg vial, the real productOXpeptides
Retatrutide 20 mg, research gradefrom $7.90/mg$6.32/mg on a first order, code FIRST20
  • Registered company OX RESEARCH LTD, no. 17464288
  • Janoshik report per size: 99.3-99.8 % purity, each vial at or above its label
  • Ships in 1-2 business days, tracked, reshipped if lost

Janoshik reports, one per size

The details

Vial (mg)Water (mL)mg/mL1 mg (units)2 mg (units)
5152040
101101020
10252040
1033.333060
202101020
303101020
Table 1. Quick chart: strength and U-100 syringe units by vial and volume of bacteriostatic water. Arithmetic only (mg divided by mL, then mL x 100).

How the retatrutide calculator works

The calculator runs three divisions, the same ones a laboratory writes on the label of a freshly mixed vial. None of them depends on the compound: they hold for any lyophilised peptide.

  1. Concentration (mg/mL) = milligrams in the vial / millilitres of water. 10 mg in 2 mL is 5 mg/mL.
  2. Volume (mL) = the mass you want / the concentration. 2 mg at 5 mg/mL is 0.4 mL.
  3. Units = millilitres x 100 on a U-100 syringe. 0.4 mL is 40 units.

The water adds nothing and removes nothing. A 10 mg vial holds 10 mg whether it is mixed with 1 mL or 3 mL; only the volume that carries each milligram changes. Why the diluent matters, how to add it without denaturing the peptide and how long a mixed vial keeps are covered in the retatrutide reconstitution guide.

Reading a U-100 syringe

"U-100" means the barrel is graduated for 100 units per millilitre, so each unit is 0.01 mL. A 1 mL syringe reads up to 100 units, a 0.5 mL syringe up to 50 and a 0.3 mL syringe up to 30. When a calculation returns more units than the barrel holds, the syringe is too small for that volume at that concentration.

That is why the choice of water volume is practical, not chemical. Less water makes a stronger solution and smaller volumes; more water makes a weaker solution and larger, easier to read volumes. For the water itself, OXpeptides bacteriostatic water (sterile water with 0.9% benzyl alcohol) is listed next to the research vials.

What the trial participants received

The published trials never used a calculator. In the phase 2 obesity trial (NEJM 2023, 338 adults), participants received 1, 4, 8 or 12 mg once weekly for 48 weeks; most arms started at 2 mg and stepped up every 4 weeks. The trial registry notes that escalation was done by increasing the injected volume of a fixed-concentration study drug prepared by the sponsor. The phase 3 TRIUMPH trials use 4, 9 and 12 mg once weekly.

These figures describe what happened in a trial, not an amount for anyone to take. Retatrutide is not approved by the FDA or the EMA; research vials are sold for research use only. The week by week ladders are in the retatrutide dosing schedule, and what the participants reported at each dose is on retatrutide side effects by dose.

Four calculation errors

Units are not milligrams. "20 units" is 0.2 mL. It holds 2 mg at 10 mg/mL and 1 mg at 5 mg/mL. Always read units together with the concentration written on the vial.

A vial label is not a dose. "10 mg" is the total powder in the vial. A 12 mg amount does not fit in one 10 mg vial at any water volume.

The wrong syringe scale. The units above assume U-100. A U-40 barrel reads 40 units per mL, and the same volume gives a different number.

Trusting the label. Every figure assumes the vial really holds what it says. Only a batch certificate of analysis (HPLC purity and mass) checks that. How the vendors of research vials compare on lot numbers and certificates is laid out on where to buy retatrutide, 13 vendors compared.

Asked and answered

How much BAC water for a 10 mg vial?

Any volume dissolves the powder; the volume only sets the concentration. 1 mL gives 10 mg/mL, 2 mL gives 5 mg/mL and 3 mL gives 3.33 mg/mL. Most reconstitution guides use 2 mL for a 10 mg vial because 5 mg/mL puts 1 mg at 20 units on a U-100 syringe, an easy number to read.

How to reconstitute 10 mg of peptide?

Add a measured volume of bacteriostatic water, let it run slowly down the inside wall of the vial rather than onto the powder, and swirl gently without shaking until the solution is clear. Write the concentration on the vial: 10 mg in 2 mL is 5 mg/mL.

How much bacteriostatic water to mix with peptides?

There is no single volume. Divide the milligrams in the vial by the concentration you want to work with: for 5 mg/mL, a 5 mg vial takes 1 mL, a 10 mg vial 2 mL and a 20 mg vial 4 mL. Choose a volume that keeps the amounts you measure within the graduations of your syringe.

What are the dosages for retatrutide?

Retatrutide has no approved dosage: it is not approved by the FDA or the EMA. In the phase 2 obesity trial (NEJM 2023), participants received 1, 4, 8 or 12 mg once weekly for 48 weeks, most starting at 2 mg; the phase 3 TRIUMPH trials use 4, 9 and 12 mg.

How many units is 2 mg of retatrutide?

It depends on the concentration. In a 10 mg vial with 2 mL of water (5 mg/mL), 2 mg is 0.4 mL, which is 40 units on a U-100 syringe. With 1 mL of water (10 mg/mL) it is 20 units; with 3 mL (3.33 mg/mL) it is 60 units.

Sources

Sources

Sources (3) · DOI · NCT
  1. [1]

    New England Journal of Medicine · 2023

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial

    Jastreboff AM, Kaplan LM, Frias JP, et al

    doi:10.1056/NEJMoa2301972
  2. [2]

    ClinicalTrials.gov · 2026

    A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight

    ClinicalTrials.gov

    https://clinicaltrials.gov/study/NCT04881760
  3. [3]

    Diabetes, Obesity and Metabolism · 2025

    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    Giblin A, et al

    doi:10.1111/dom.70209